Paired - Patient Reported Experiences and Perceived Benefit of Treatment with Dolutegravir/Lamivudine: Interim Analysis (N =100)
Author(s)
Slim J1, Brogan A2, Harper G3, Mycock K3, McMillan A3, Verdier G2
1Saint Michael's Medical Center, Newark, NJ, USA, 2ViiV Healthcare, Durham, NC, USA, 3Adelphi Real World, Bollington, UK
Presentation Documents
OBJECTIVES:
PAtIent Reported Experiences and perceiveD benefit of treatment with dolutegravir/lamivudine (PAIRED) is a cross-sectional survey of people living with HIV-1 (PLWH) switching to dolutegravir/lamivudine from a previous antiretroviral regimen set to enroll 500 participants. Interim analysis is presented.METHODS:
This cross-sectional survey of stable-switch PLWH ≥18 years receiving dolutegravir/lamivudine for ≥3 months in the US has a mixed recruitment methodology (site-led and community outreach). Stable-switch PLWH were defined as having HIV-1 RNA <50 copies/mL and on a stable antiretroviral treatment regimen for ≥3 months upon dolutegravir/lamivudine initiation. This interim analysis includes 100 PLWH who completed the survey. Analyses were descriptive.RESULTS:
With 100 completed surveys, PAIRED represents a diverse sample with 26% female sex at birth, 41% non-white, and 57% ≥50 years. Median participant age was 52 years (IQR: 40.2-62.0). Participants had an average time since HIV diagnosis of 18 years (IQR: 8.2-28.0) and most (68%) had taken at least 3 previous antiretroviral regimens. The majority (54%) had taken 3-drug integrase-based regimens before switching to dolutegravir/lamivudine and 40% had taken immediate previous treatment for >24 months. Most participants (63%) had taken dolutegravir/lamivudine for >12 months. Almost all participants (98%) indicated prior awareness of dolutegravir/lamivudine being a 2-drug regimen. Switch discussions were PLWH-initiated 31% of the time. The top 3 most commonly selected reasons for switching to dolutegravir/lamivudine were avoidance of side-effects, minimization of long-term impact of HIV treatment, and reduction of build-up of drugs over time. 76% of participants were very satisfied with dolutegravir/lamivudine (score of 6 out of 6) and 93% of participants were somewhat satisfied or above (score of 4-6). Self-reported adherence was high for both previous regimen and dolutegravir/lamivudine (1.8 average reported missed doses within a 60-day period).CONCLUSIONS:
This interim analysis represents a diverse sample, and PLWH surveyed are satisfied with switching to dolutegravir/lamivudine.Conference/Value in Health Info
2023-05, ISPOR 2023, Boston, MA, USA
Value in Health, Volume 26, Issue 6, S2 (June 2023)
Code
PCR207
Topic
Patient-Centered Research
Topic Subcategory
Adherence, Persistence, & Compliance, Patient Behavior and Incentives, Patient Engagement, Patient-reported Outcomes & Quality of Life Outcomes
Disease
No Additional Disease & Conditions/Specialized Treatment Areas